TCGA-D8-A146-01A-31R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 21
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.919 |
| 2 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.908 |
| 3 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.905 |
| 4 | 20020009.LumA | — | A | 0.897 |
| 5 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.892 |
| 6 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.891 |
| 7 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.873 |
| 8 | SRR8613790 | — | A | 0.871 |
| 9 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.869 |
| 10 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |